National COVID-19 Research

The National Institute for Health Research (NIHR) have released a list of frequently asked questions about COVID-19 research taking place in the UK. So far, over 30,000 participants are taking part in a range of NIHR supported COVID-19 research studies across the UK. There are 21 new research studies into the novel coronavirus that have […]

read more

NHS warning to seek help for cancer symptoms, as public report concerns with getting checked

Professor Peter Johnson, England’s top cancer doctor, has urged people not to hesitate to get checked for cancer as new research revealed that nearly half of the public have concerns about seeking help during the coronavirus pandemic. The survey found that one in 10 people would not contact their GP even if they had a […]

read more

COVID-19 extremely vulnerable group of people to increase to 2 million

The number of extremely vulnerable people at high risk of coronavirus who have been asked to “shield” themselves for 12 weeks is to be increased to two million people by the end of the month. Initially, the shielding group was expected to be around 1.5 million people, but GPs have been “overwhelmed with requests” and […]

read more

NHS Help Us Help You campaign

The NHS has launched a major new drive to persuade the public to seek the urgent care and treatment they need and that, despite COVID-19, the NHS is open for business. Delays in getting treatment due to coronavirus fears pose a long term risk to people’s health. In addition, fewer people are going to their […]

read more

Targeted therapy dose reduction resulted in better clinical outcomes

A recent post hoc analysis of the results from the COMPARZ clinical trial, which compared first-line treatment with pazopanib versus sunitinib for metastatic renal cell carcinoma (RCC), was published in Clinical Genitourinary Cancer last February 2020. During the COMPARZ study, pazopanib and sunitinib (VEGF-TKI targeted therapy) had similar efficacy. However, this analysis showed that the […]

read more

Atezolizumab alone or in combination with bevacizumab for untreated metastatic kidney cancer

This paper reports patient-reported outcomes from the phase 2 IMmotion150 study to assess the safety and efficacy of atezolizumab alone or in combination with bevacizumab versus sunitinib in 305 untreated metastatic renal cell carcinoma (RCC) patients. For all patients in the study, objective response rates were 25%, 32%, and 29% for atezolizumab alone, atezolizumab plus […]

read more

Living Well UK offering free talking therapy during COVID-19 pandemic to people in Birmingham

Living Well UK are offering free talking therapies for people within the Birmingham and Solihull Clinical Commissioning Group (CCG) locality. Patients need to be referred by their GP for this service. Living Well offers qualified practitioners who offer talking therapy to support patients who are suffering anxiety and or depression as a result of their […]

read more

Cryoablation is safe and effective for small kidney tumours

A new study published in the American Journal of Roentgenology confirms that image-guided percutaneous cryoablation is a safe and efficacious treatment for selected small renal cell carcinoma (RCC) tumours. Cryoablation is a non-invasive technique, which involves ‘freezing’ the tumour using fine needles inserted through the skin (percutaneous). This technique has not yet been widely adopted […]

read more

Positive results from trial of cabozantinib plus nivolumab combination in untreated metastatic kidney cancer

Results from the pivotal phase 3 CheckMate-9ER clinical trial evaluating nivolumab (Opdivo) in combination with cabozantinib (Cabometyx) compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma (RCC) were released today. These top-line results were positive for the combination treatment, which improved progression-free survival, overall survival and objective response rate compared to sunitinib. […]

read more

Cabozantinib in combination with immunotherapy for advanced kidney cancer

In this video interview, Dr Monty Pal from the City of Hope cancer centre in California, USA, talks about the clinical trials involving cabozantinib in combination with atezolizumab for clear cell and non-clear cell renal cell carcinoma (RCC). Watch the video interview on Practice Update here  

read more
Showing 21 to 30 of 784 results
  TOP